<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28832/agents-in-the-2nd-line-setting-in-rcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Agents in the 2nd Line Setting in RCC

Name: Agents in the 2nd Line Setting in RCC
Uploaded: 2019-06-26T05:05:43
Duration: 44 s
Description: Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center elaborates on the preferred agents on the 2nd line setting of renal cell carcinoma if a patient progresses on pembrolizumab/axitinib or ipilimumab/nivolumab.

00:00:44

Don

3 years 63 Views

Share Add to Report 0 0

Embed (Iframe):

<div class="embed-responsive embed-responsive-16by9"><iframe width="640" height="360" style="max-width: 100%;max-height: 100%; border:none;" src="https://oncologytube.com/videoEmbed/28832/agents-in-the-2nd-line-setting-in-rcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" frameborder="0" allowfullscreen="allowfullscreen" allow="autoplay" scrolling="no">iFrame is not supported!</iframe></div>

Embed (Object):

<div class="embed-responsive embed-responsive-16by9"><object width="640" height="360"><param name="movie" value="https://oncologytube.com/videoEmbed/28832/agents-in-the-2nd-line-setting-in-rcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit="></param><param name="allowFullScreen" value="true"></param><param name="allowscriptaccess" value="always"></param><embed src="https://oncologytube.com/videoEmbed/28832/agents-in-the-2nd-line-setting-in-rcc?channelName=obr&modestbranding=1&showinfo=1&autoplay=&controls=1&loop=&mute=&t=0&objectFit=" allowscriptaccess="always" allowfullscreen="true" width="640" height="360"></embed></object></div>

Link (HTML):

<a href="https://oncologytube.com/v/28832?channelName=obr"><img src="https://oncologytubecom.cdn.ypt.me/videos/video_190626170543_b398/video_190626170543_b398.jpg?cache=15669161611678829655">Agents in the 2nd Line Setting in RCC</a>

Link (BBCode):

[url=https://oncologytube.com/v/28832?channelName=obr][img]https://oncologytubecom.cdn.ypt.me/videos/video_190626170543_b398/video_190626170543_b398.jpg?cache=15669161611678829655[/img]Agents in the 2nd Line Setting in RCC[/url]

Sign in now!

Permanent Link

URL Friendly (SEO)

Current Time (SEO)

Category:

Prostate

Description:

Nancy A. Dawson MD, Professor of Medicine at Lombardi Cancer Center elaborates on the preferred agents on the 2nd line setting of renal cell carcinoma if a patient progresses on pembrolizumab/axitinib or ipilimumab/nivolumab.